SEC Form 4 · accession 0002001011-26-000111

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Andrew Reardon

Officer — CLO & Secretary

Period of report

Aug 3, 2026

Accepted (ET)

Aug 4, 2026 · 6:42 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Aug 3, 2026	M	5,000	$52.27	A	46,514	D
Common Stock^F1,F2	Aug 3, 2026	S	105	$284.1375	D	46,409	D
Common Stock^F1,F3	Aug 3, 2026	S	33	$284.553	D	46,376	D
Common Stock^F1,F4	Aug 3, 2026	S	157	$285.7357	D	46,219	D
Common Stock^F1,F5	Aug 3, 2026	S	1,032	$286.7968	D	45,187	D
Common Stock^F1,F6	Aug 3, 2026	S	1,214	$287.7731	D	43,973	D
Common Stock^F1,F7	Aug 3, 2026	S	356	$288.7496	D	43,617	D
Common Stock^F1,F8	Aug 3, 2026	S	503	$289.8022	D	43,114	D
Common Stock^F1,F9	Aug 3, 2026	S	200	$290.60	D	42,914	D
Common Stock^F1,F10	Aug 3, 2026	S	991	$291.7119	D	41,923	D
Common Stock^F1,F11	Aug 3, 2026	S	409	$292.8191	D	41,514	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1,F12	$52.27	Aug 3, 2026	M	5,000	D	—	Aug 1, 2032	Common Stock	5,000	29,444	D

Explanation of responses

F1The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.
F10The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $291.57 to $292.47. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.78 to $292.89. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.24 to $284.23. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.28 to $284.58. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.28 to $285.90. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $286.28 to $287.17. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.30 to $288.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.32 to $289.20. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $289.33 to $290.18. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $290.48 to $290.72. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.